Cambridge-based pharmaceuticals firm Avacta has partnered with Korean conglomerate, LG Chem company, to develop a new generation of cancer drugs.
Avacta’s Affimer technology acts as an alternative to antibodies by treating conditions that antibodies cannot remedy – image courtesy of Pixabay Avacta, whose Affimer technology is an engineered alternative to antibodies, will be tasked with generating and carrying out the discovery, optimisation and protein engineering of Affimer drug candidates. They will also…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
